EUVIMEDEUVIMED entdecken
Open Access

Pathological response and tumor stroma immunogenic features predict long-term survival in non-small cell lung cancer after neoadjuvant chemotherapy

Shuaibo Wang, Xujie Sun, Jiyan Dong, Li Liu, Hao Zhao, Renda Li, Zhenlin Yang, Na Cheng, Yalong Wang, Li Fu, Hang Yi, Zhuoheng Lv und 4 weitere

Cellular Oncology · 2024-06 · 47 (3) · 1005-1024

DOI: 10.1007/s13402-023-00914-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cellular Oncology, online erschienen am 06.02.2024. Verfasst von Shuaibo Wang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Scien…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Neoadjuvant Therapy, Lung Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Sciences Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungNeoadjuvant TherapyLung NeoplasmsHumansFemaleMaleMiddle AgedAgedRetrospective StudiesPrognosisAdultTreatment Outcome

Stichwörter der Autor:innen

Major pathological response (MPR)Neoadjuvant chemotherapy (NAC)Non-small cell lung cancer (NSCLC)Pathologic tumor stage (ypTNM)Prognosis

Autor:innen und Institutionen

  • Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
  • Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
  • Surgery Centre of Diabetes Mellitus, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100036, China.
  • Department of Anesthesiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
  • Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. yousheng…
  • Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. linyang0616@126…

Förderung

  • National Natural Sciences Foundation

Zitieren

APA

Wang, S., Sun, X., Dong, J., Liu, L., Zhao, H., Li, R., Yang, Z., Cheng, N., Wang, Y., Fu, L., Yi, H., Lv, Z., Huo, H., Jin, D., Mao, Y., & Yang, L. (2024). Pathological response and tumor stroma immunogenic features predict long-term survival in non-small cell lung cancer after neoadjuvant chemotherapy. Cellular Oncology, 47(3), 1005-1024. https://doi.org/10.1007/s13402-023-00914-6

Vancouver

Wang S, Sun X, Dong J, Liu L, Zhao H, Li R, et al. Pathological response and tumor stroma immunogenic features predict long-term survival in non-small cell lung cancer after neoadjuvant chemotherapy. Cellular Oncology. 2024;47(3):1005-1024. doi:10.1007/s13402-023-00914-6

BibTeX
@article{Wang2024,
  author = {Wang, Shuaibo and Sun, Xujie and Dong, Jiyan and Liu, Li and Zhao, Hao and Li, Renda and Yang, Zhenlin and Cheng, Na and Wang, Yalong and Fu, Li and Yi, Hang and Lv, Zhuoheng and Huo, Huandong and Jin, Donghui and Mao, Yousheng and Yang, Lin},
  title = {Pathological response and tumor stroma immunogenic features predict long-term survival in non-small cell lung cancer after neoadjuvant chemotherapy},
  journal = {Cellular Oncology},
  year = {2024},
  volume = {47},
  number = {3},
  pages = {1005--1024},
  doi = {10.1007/s13402-023-00914-6}
}
Kostenlos starten →